✦ LIBER ✦

P035 Sequential targeted therapy with sunitinib-sorafenib (SU-SO) versus sorafenib-sunitinib (SO-SU) in metastatic renal cell carcinoma: Results from a large cohort of patients

✍ Scribed by Biondani, P.; Verzoni, E.; Torri, V.; Porcu, L.; De Braud, F.; Procopio, G.

Book ID: 122229999
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 65 KB
Volume: 12
Category: Article
ISSN: 1569-9056
DOI: 10.1016/S1569-9056(13)62361-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase III Trial of Temsirolim

Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

✍ Hutson, T. E.; Escudier, B.; Esteban, E.; Bjarnason, G. A.; Lim, H. Y.; Pittman, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 258 KB

Tivozanib Versus Sorafenib As Initial Ta

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

✍ Motzer, R. J.; Nosov, D.; Eisen, T.; Bondarenko, I.; Lesovoy, V.; Lipatov, O.; T 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 196 KB